Plain-English translation of NCT05955326 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
This trial is testing whether a medication called can help people recover better after an acute ischemic stroke (when a blood clot blocks blood flow to the brain). The medication is designed to help the brain repair itself by promoting the growth of new brain cells and blood vessels, protecting cells from damage, and improving blood flow to the injured area. Half the participants will receive along with standard stroke treatment, while the other half will receive standard treatment alone, so researchers can compare how well the new medication works.
Current stroke treatments help in the immediate hours after a stroke, but many patients are left with significant disabilities. This medication is designed to support the brain's natural healing processes in the days after a stroke, potentially helping patients recover more function and independence than standard treatment alone.
You likely qualify if…
You likely don't qualify if…
If you qualify and enroll, you will be randomly assigned to receive either the new medication or a placebo (salt water) along with your regular stroke care. You will receive three injections through an IV line on day 1, day 3, and day 6 after your stroke, with about 3 hours between each dose. You will have three study visits over 3 months where doctors will check your recovery progress, test your strength and brain function, and monitor you for any side effects.
AI-generated summary from trial data · Jul 19, 2026 · Not medical advice
India